RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as personalized content. Please see our Privacy Policy for more information.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

03 July 2020
Today's update includes new information on Veklury, Kaletra, EID-2801, AdMSCs and PTC299.

Latest News

ALL
02 July 2020
Artificial intelligence is not ready for autonomy in radiology, according to two radiological professional associations who asked the US Food and Drug Administration (FDA) to wait for more rigorous testing and surveillance of the modality before a...
02 July 2020
The RAPS Convergence conference will transition to a virtual-only experience for the first time ever in 2020, with two registration options for its upcoming annual event, which was originally planned to convene in San Antonio, TX.
02 July 2020
RAPS has just published the updated, ninth edition of Fundamentals of EU Regulatory Affairs. The book remains the most extensive reference available on regulatory affairs for pharmaceuticals, medical devices and biologics for the European market.
02 July 2020
FDA requested the NASEM review due to increasing popularity of compounded bioidentical hormone therapies combined with concerns over healthcare providers’ and patients’ understanding of the uncertain benefits and potential risks associated with th...
02 July 2020
Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news.
02 July 2020
This update includes new information on vaccine candidates from Bharat Biotech/National Institute of Virology, Inovio, CanSino Biologics, Vaxine Pty Ltd., Pfizer/BioNTech and Vaxart. 

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.